Title: Race Against Time: Three Experimental Ebola Vaccines Target Emerging Outbreak

Amid escalating fears of a major Ebola outbreak, three distinct vaccine candidates are currently under development to combat the rare Bundibugyo species, which has already claimed nearly 250 lives. The International Aids Vaccine Initiative (IAVI), one of the organizations leading the charge, warned that the current crisis threatens to become the most severe in the disease’s history.

The urgency is underscored by data from the Democratic Republic of Congo (DR Congo) and neighboring Uganda, where authorities have identified over 1,000 suspected cases and nine confirmed infections. The Coalition for Epidemic Preparedness Innovations (CEPI), which is funding the research efforts of IAVI, the University of Oxford, and pharmaceutical giant Moderna, emphasized that “every day counts” in this critical window.

Health experts are deeply concerned that this outbreak, which was identified only after it had taken hold in a conflict zone with scarce medical infrastructure, could mirror the scale of the 2014–2016 West Africa epidemic. That previous crisis resulted in approximately 29,000 infections and over 11,000 deaths. Dr. Mark Feinberg, head of IAVI, stated, “I think this is clearly threatening to be as severe an outbreak as that, if not even worse, and development of a vaccine, and other countermeasures, is clearly a priority.”

This sentiment is echoed by Médecins Sans Frontières (MSF), the medical charity that described the situation as “deeply alarming,” noting that it had never before witnessed such a high volume of cases emerge so rapidly.

Unlike the Zaire species, for which an approved vaccine exists, the Bundibugyo virus is far less common and currently lacks any licensed immunization. It has been responsible for outbreaks only twice before. Because vaccines are species-specific, the existing Zaire vaccine is ineffective against this new threat. Consequently, IAVI is engineering a modified version of the Zaire vaccine to target Bundibugyo. Preliminary tests in monkeys showed promising results, with the experimental jab rapidly stimulating the immune system and providing nearly 100% protection. Despite this optimism, Feinberg noted that it would still take seven to nine months to prepare the vaccine for human clinical trials, though the team is striving to accelerate the process.

Meanwhile, Moderna is leveraging its mRNA technology—famously utilized for rapid Covid-19 vaccine development—to create a Bundibugyo candidate. “We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most,” said Stéphane Bancel, Moderna’s chief executive officer.

The University of Oxford is also advancing its own vaccine platform, utilizing technology that proved vital during the pandemic, with plans to have a candidate ready for clinical trials within two to three months.

All three initiatives share a common goal: training the body to recognize the Bundibugyo glycoprotein, a specific structure on the virus’s surface. However, their methods differ significantly. IAVI’s approach employs a harmless, engineered virus carrying the Ebola glycoprotein, prompting the immune system to learn how to fight the virus while neutralizing the harmless vector. In contrast, both Moderna’s mRNA vaccine and Oxford’s candidate deliver genetic snippets into the body. These instructions direct cells to produce the glycoprotein, triggering an immune response against this foreign protein.

These mechanisms provide the immune system with a preparatory advantage before any real infection occurs. Nevertheless, variations in technology and immune training may influence the degree of protection offered or the dosage required, necessitating rigorous clinical trials to determine efficacy.

CEPI is supporting the early-stage research for all three projects. Dr. Richard Hatchett, CEPI’s CEO, highlighted the stakes: “With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease.”

Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, added that a successful Bundibugyo vaccine would be instrumental in controlling the spread, though his comments in the original report were cut off.

Source: BBC News Generated at: 2026-06-01 14:30:39 UTC